The Wegovy dose schedule: what it is and why it works that way

The myth that the starter dose is not 'doing anything'

The question our prescribers hear most weeks goes something like: "I've been on 0.25 mg for a month and barely noticed a difference, when does it actually start working?" It's an understandable question, and the honest answer is that 0.25 mg is not designed to produce substantial weight loss. Its job is to let your digestive system adjust to semaglutide before the dose climbs to a level where appetite suppression becomes meaningful.

Semaglutide works by activating GLP-1 receptors involved in hunger signalling and gastric emptying. At lower doses, those effects are present but mild. The therapeutic benefit builds as the dose rises. Clinical trial participants who went on to lose an average of around 15% of their body weight over 68 weeks (reported in the STEP 1 trial published in the New England Journal of Medicine) all went through the same slow start. Patience during the early steps is not wasted; it is how the medicine is supposed to be used.

Tolerance also varies. Some people sail through the 0.25 mg and 0.5 mg steps with little trouble; others find even those lower doses bring noticeable nausea. Starting low gives your prescriber information that shapes every subsequent decision about your full dose progression.

The UK Wegovy dose steps, from first pen to maintenance

The licensed UK titration for Wegovy injection runs as follows, with each step lasting approximately four weeks: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg as the standard maintenance dose. For patients who need or tolerate more, the MHRA approved a 7.2 mg maintenance option, initially delivered as three 2.4 mg pens used weekly, and from 14 April 2026 as a single dedicated pen. The maximum licensed dose is now 7.2 mg.

Trials of the 7.2 mg dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap considerably with the results seen from tirzepatide at its highest doses. That said, the 7.2 mg pen is licensed specifically for adults with a BMI of 30 or above; it is not approved for the cardiovascular indication or for people below that BMI threshold. If you are already established on 2.4 mg weekly injections, a move to 7.2 mg is a clinical conversation, not an automatic upgrade.

The four-week minimum at each step is not arbitrary. It roughly matches the time semaglutide takes to reach steady-state blood levels at that dose, and it gives your body a fair window to adjust before things change again. Rushing ahead is one of the more common reasons people find the medicine difficult to tolerate. Details of each individual pen and the doses it delivers are covered in the pen-by-pen guide on this site.

Who the dose schedule applies to, and when a prescriber might pause it

The schedule above applies to adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. BMI alone does not settle the question; a prescriber reviews your full picture. Lower BMI thresholds apply for some ethnic backgrounds under NICE's guidance on semaglutide (TA875).

A prescriber may pause the titration, or keep you at a lower dose for longer, if side effects are persistent or severe. That is not a failure, it is exactly how the medicine is intended to be managed. Common side effects cluster around the gastrointestinal system: nausea, loose stools, constipation, reflux and reduced appetite are reported most often, particularly in the first week or two after a dose increase. They usually settle. If you experience severe, persistent abdominal pain that spreads to your back, that needs medical attention promptly; the MHRA highlighted acute pancreatitis as a known, though infrequent, risk in its January 2026 Drug Safety Update on GLP-1 medicines.

Pregnancy, breastfeeding and actively trying to conceive are all situations in which Wegovy is not recommended, regardless of dose. Under-18s are not a licensed population. These are not edge cases to navigate around; they are clinical boundaries a prescriber applies at every review, including repeats. Further context on who qualifies and what the injection strengths mean practically is worth reading before your consultation.

NHS prescribing versus private treatment: what changes and what doesn't

On the NHS, Wegovy is available through specialist weight management services under NICE TA875, with waiting lists that are commonly long. The dose schedule is exactly the same whether you receive it through the NHS or through a regulated private pharmacy, semaglutide is semaglutide, and the titration is set by the medicine's licence, not by the route of access. What differs is the speed, the criteria, and the support structure around it.

Privately, there is no referral required and no waiting list. A consultation with a GPhC-registered prescriber (at a service like nume, sorry, like ours) takes place the same day you apply, with real clinical review of your answers, medical history and weight verification. If you are clinically suitable, treatment can be dispatched the same day for next-working-day delivery. The wider landscape of licensed weight-loss treatments in the UK is worth understanding before you decide which route suits you. For a full cost picture, the Wegovy pricing and access page sets out what private treatment involves.

The titration schedule remains the clinical constant throughout. Whatever route you take, no prescriber who is following MHRA-approved guidance will hand you 2.4 mg on day one. That pace of escalation is the medicine working as intended.